Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story

EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story Drugs that target the epidermal growth factor receptor (EGFR) have had a major impact on the treatment of non–small cell lung cancer (NSCLC). The use of these drugs has also motivated pivotal advances in the understanding of the molecular biology of NSCLC, including the discovery that mutations in EGFR are associated with dramatic and sustained responses to anti-EGFR treatments. This review summarizes the clinical development of EGFR tyrosine kinase inhibitors, the discovery of molecular predictors of response, and the future directions for research in the field. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annual Review of Medicine Annual Reviews

EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story

Loading next page...
 
/lp/annual-reviews/egfr-tyrosine-kinase-inhibitors-in-lung-cancer-an-evolving-story-Q3Sgp0ohou

References (77)

Publisher
Annual Reviews
Copyright
Copyright © 2008 by Annual Reviews. All rights reserved
ISSN
0066-4219
eISSN
1545-326X
DOI
10.1146/annurev.med.59.090506.202405
pmid
17716025
Publisher site
See Article on Publisher Site

Abstract

Drugs that target the epidermal growth factor receptor (EGFR) have had a major impact on the treatment of non–small cell lung cancer (NSCLC). The use of these drugs has also motivated pivotal advances in the understanding of the molecular biology of NSCLC, including the discovery that mutations in EGFR are associated with dramatic and sustained responses to anti-EGFR treatments. This review summarizes the clinical development of EGFR tyrosine kinase inhibitors, the discovery of molecular predictors of response, and the future directions for research in the field.

Journal

Annual Review of MedicineAnnual Reviews

Published: Feb 18, 2008

There are no references for this article.